KALYDECO™ (ivacaftor) is a prescription medicine for the treatment of cystic fibrosis in patients ages six years and older who have the specific G551D mutation in the Cystic Fibrosis Transmembrane Regulator (CFTR) gene. In Canada, the number of patients with this mutation is about 100. KALYDECO™, a pill taken twice a day with fat-containing food, helps the protein made by the CFTR gene function better and, as a result, improves lung function and other aspects of cystic fibrosis such as increasing weight.
On November 26th, 2012, Health Canada approved KALYDECO™ for use in Canada. On March 26th, 2013, it was announced that the Canadian Drug Expert Committee recommends that KALYDECO be listed on the formulary listing of publicly funded drug plans for the treatment of cystic fibrosis in patients age six years and older who have the G551D mutation in the Cystic Fibrosis Transmembrane conductance Regulator. Quebec has its own drug review process through the Institut national d'excellence en santé et en services sociaux (INESSS).
Alberta Health has taken the lead on behalf of provinces in negotiations with Vertex Pharmaceuticals as part of the pan-Canadian pricing alliance process.
Sign our petition to Alberta Premier Alison Redford and Health Minister Fred Horne asking them to ensure that CF patients who need Kalydeco have access to this drug as soon as possible.
Read our blog to learn more about Cystic Fibrosis Canada’s advocacy efforts on KALYDECO™.
You can help support our important advocacy initiatives by making a donation to Cystic Fibrosis Canada. Every dollar helps us raise the voice of Canadian CF patients as we fight for access to much needed medicines and for CF screening for newborn babies.
kalydeCARE™ is a Patient Assistance Program for patients who have been have been prescribed KALYDECO by their health care provider. For more information please call: 1-855-CARE-571 (1-855-227-3571).